Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye care

On November 9, 2026, the US Food and Drug Administration (FDA) issued a Drug Safety Communication requiring safety labeling changes for the entire class of GLP-1 RAs, citing a potential increased risk of NAION.¹ The agency’s decision drew on a pooled analysis of 126 randomized controlled trials covering 134,253 patients, which found an incidence of 6.4 NAION events per 100,000 person-years with GLP-1 RAs vs 3.8 per 100,000 person-years with comparators.^1,2